XCUR
Exicure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.25
+1.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 500.0K | — | 28.8M |
| Cost of Revenue | 263.0K | 460.0K | — | 1.4M | 1.9M |
| Gross Profit | (263.0K) | (460.0K) | 500.0K | (1.4M) | 27.0M |
| Operating Expenses | |||||
| R&D Expense | 2.0M | 3.3M | — | 1.4M | 19.8M |
| SG&A Expense | 5.2M | 6.8M | 5.4M | 12.7M | 10.9M |
| General & Admin Expense | 5.2M | 6.8M | 5.4M | 12.7M | 10.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (162.0K) | (460.0K) | 7.3M | (503.0K) | (1.9M) |
| Total Operating Expenses | 7.0M | 9.7M | 12.7M | 13.6M | 28.8M |
| Cost and Expenses | 7.3M | 10.1M | 12.7M | 15.0M | 30.7M |
| Operating Income (EBIT) | (7.3M) | (10.1M) | (12.2M) | (15.0M) | (1.8M) |
| Non-Operating | |||||
| Interest Income | 31.0K | 29.0K | 8.0K | 32.0K | 15.0K |
| Interest Expense | 1.0K | 1.0K | 18.0K | — | 595.0K |
| Net Interest Income | 30.0K | 28.0K | (10.0K) | 32.0K | (580.0K) |
| Other Non-Op Income/Expense | (1.6M) | 4.5M | 2.5M | (1.9M) | (542.0K) |
| Non-Operating Income (excl Interest) | 1.6M | (4.5M) | (2.6M) | 1.9M | (53.0K) |
| EBT (Pre-Tax Income) | (8.9M) | (5.6M) | (9.7M) | (16.9M) | (2.4M) |
| Income Tax Expense | (634.0K) | (634.0K) | 8.0K | — | 209.0K |
| Bottom Line | |||||
| Net Income | (8.3M) | (4.9M) | (9.7M) | (16.9M) | (2.6M) |
| Earnings from Cont. Ops | (8.3M) | (4.9M) | (9.7M) | (16.9M) | (2.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.3M) | (4.9M) | (9.7M) | (16.9M) | (2.6M) |
| Per Share | |||||
| Basic EPS | ($1.31) | ($0.79) | ($1.59) | ($2.11) | ($0.56) |
| Diluted EPS | ($1.31) | ($0.79) | ($1.59) | ($2.11) | ($0.56) |
| Revenue Per Share | $0.00 | $0.00 | $0.08 | $0.00 | $6.24 |
| Shares | |||||
| Basic Shares Outstanding | 6.4M | 6.3M | 6.1M | 8.0M | 4.6M |
| Diluted Shares Outstanding | 6.4M | 6.3M | 6.1M | 8.0M | 4.6M |
| Profitability Metrics | |||||
| EBITDA | (8.5M) | (5.1M) | (8.9M) | (15.5M) | 78.0K |
| D&A | 374.0K | 460.0K | 824.0K | 1.4M | 1.9M |
| EBIT | (8.9M) | (5.6M) | (9.7M) | (16.9M) | (1.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026